An appeals court dealt a blow to the US Federal Trade Commission in eliminating a $448m disgorgement award to the agency in its suit against AbbVie Inc. over AndroGel patent settlements. But it revived the FTC’s reverse-payment claims regarding AbbVie’s agreement with Teva Pharmaceuticals USA Inc.
The decision keeps the complaint alive and gives support to FTC’s long-running battle against so-called “pay-for-delay” settlements between brand and...





